Stanford, CA, United States
Stanford, CA, United States

Leland Stanford Junior University, or more commonly Stanford University, is a private research university in Stanford, California, and one of the world's most prestigious institutions, with the highest undergraduate selectivity and the top position in numerous surveys and measures in the United States.Stanford was founded in 1885 by Leland Stanford, former governor of and U.S. senator from California and leading railroad tycoon, and his wife, Jane Lathrop Stanford, in memory of their only child, Leland Stanford, Jr., who had died of typhoid fever at age 15 the previous year. Stanford was opened on October 1, 1891 as a coeducational and non-denominational institution. Tuition was free until 1920. The university struggled financially after Leland Stanford's 1893 death and after much of the campus was damaged by the 1906 San Francisco earthquake. Following World War II, Provost Frederick Terman supported faculty and graduates' entrepreneurialism to build self-sufficient local industry in what would later be known as Silicon Valley. By 1970, Stanford was home to a linear accelerator, and was one of the original four ARPANET nodes .Stanford is located in northern Silicon Valley near Palo Alto, California. The University's academic departments are organized into seven schools, with several other holdings, such as laboratories and nature reserves, located outside the main campus. Its 8,180-acre campus is one of the largest in the United States. The University is also one of the top fundraising institutions in the country, becoming the first school to raise more than a billion dollars in a year.Stanford's undergraduate program is the most selective in the country with an acceptance rate of 5.07% for the 2018 Class. Students compete in 36 varsity sports, and the University is one of two private institutions in the Division I FBS Pacific-12 Conference. It has gained 105 NCAA team championships, the second-most for a university, 465 individual championships, the most in Division I, and has won the NACDA Directors' Cup, recognizing the university with the best overall athletic team achievement, every year since 1994-1995.Stanford faculty and alumni have founded many companies including Google, Hewlett-Packard, Nike, Sun Microsystems, and Yahoo!, and companies founded by Stanford alumni generate more than $2.7 trillion in annual revenue, equivalent to the 10th-largest economy in the world. Fifty-nine Nobel laureates have been affiliated with the University, and it is the alma mater of 30 living billionaires and 17 astronauts. Stanford has produced a total of 18 Turing Award laureates, the highest in the world for any one institution. It is also one of the leading producers of members of the United States Congress. Wikipedia.


Time filter

Source Type

Patent
Stanford University | Date: 2017-03-29

Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided


Patent
Stanford University | Date: 2017-01-13

The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.


Methods, systems and devices are implemented in connection with light- responsive ion channel molecules. One such method is implemented using a light- activated ion channel molecule that responds to a light stimulus. The method includes engineering the light-activated ion channel molecule in a cell; and activating the ion channel molecule, in response to light stimulus that is provided to the ion channel molecule and that has properties that do not activate a ChR2 ion channel, to allow ions to pass through the light-activated ion channel molecule.


Patent
Stanford University | Date: 2017-01-11

A method of forming a sulfur-based cathode material includes: 1) providing a sulfur-based nanostructure; 2) coating the nanostructure with an encapsulating material to form a shell surrounding the nanostructure; and 3) removing a portion of the nanostructure through the shell to form a void within the shell, with a remaining portion of the nanostructure disposed within the shell.


Patent
Stanford University | Date: 2017-01-11

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.


Anti-SIRP antibodies, including multi-specific anti-SIRP antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP and can block the interaction of CD47 on one cell with SIRP on a phagocytic cell. Antibodies that are bispecific for SIRP and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti SIRP antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP antibodies.


Patent
Vib Vzw, Vrije Universiteit Brussel and Stanford University | Date: 2017-01-18

The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.


A 1-ADR agonist prodrug compound, which is hydrolysable in vivo to release a 1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound relative to the 1-ADR agonist compound.


Steinman L.,Stanford University
Annual Review of Immunology | Year: 2014

Eighty percent of individuals with multiple sclerosis (MS) initially develop a clinical pattern with periodic relapses followed by remissions, called relapsing-remitting MS (RRMS). This period of fluctuating disease may last for a decade or more. Clinical relapses reflect acute inflammation in the central nervous system (CNS), composed of the brain and spinal cord. Often, different anatomic areas in the CNS are involved each time a relapse occurs, resulting in varied clinical manifestations in each instance. Relapses are nearly always followed by some degree of remission, though recovery to baseline status before the flare is often incomplete. There are nine approved drugs for treatment of RRMS. The most potent drug for inhibiting relapses, the humanized anti-α4 integrin antibody known as Natalizumab, blocks homing of mononuclear cells to the CNS. The mechanisms of action of the approved drugs for RRMS provide a strong foundation for understanding the pathobiology of the relapse. Despite substantial progress in controlling relapses with the current armamentarium of medications, there is much to learn and ever more effective and safe therapies to develop. © 2014 by Annual Reviews. All rights reserved.


Hartnoll S.A.,Stanford University
Nature Physics | Year: 2015

The anomalous transport of important materials such as high-temperature superconductors and other 'bad metals' is not well understood theoretically. In an incoherent metal, transport is controlled by the collective diffusion of energy and charge rather than by quasiparticle or momentum relaxation. Here, we explore the possibility of a universal bound D ≳hv2 F/(KBT) on the underlying diffusion constants in an incoherent metal. Such a bound is loosely motivated by results from holographic duality, the uncertainty principle and measurements of diffusion in strongly interacting non-metallic systems. Metals close to saturating this bound are shown to have a linear-in-temperature resistivity with an underlying dissipative timescale matching that recently deduced from experimental data on a wide range of metals. This bound may therefore be responsible for the ubiquitous appearance of high-temperature regimes in metals with T-linear resistivity. To establish this calls for direct measurements of diffusive processes and of charge susceptibilities in incoherent metals. © 2014 Macmillan Publishers Limited. All rights reserved.

Loading Stanford University collaborators
Loading Stanford University collaborators